Upcoming Event: IMPACT 2020 R&D Day
时间：2020-10-27 17:35:39
IMPACT 2020 R&D Day will be held on Oct 30, 2020 at Grand Hyatt Shanghai Hotel, China. This event is an invitation-only, one-day event featuring four lectures in the morning by Impact SAB members, who are prominent scientists and clinicians. In the afternoon, Impact management will present the pipeline progress, followed by discussions and social interactions with attendees. To accommodate off-site audience, the event will be simultaneously broadcasted on-line.
The theme of the inaugural IMPACT 2020 R&D Day is Hallmarks of Cancer and Synthetic Lethality. One of the hallmarks of cancer is genome instability and mutation. PARP inhibitors have been developed as therapeutics targeted to this particular cancer hallmark. In addition, genome instability and mutation in cancer cells render them more dependent on alternative pathways so these cancer cells are more vulnerable to targeted therapeutic perturbations on those alternative pathways – a phenomenon known as synthetic lethality. At Impact, we have concentrated our R&D efforts on exploring synthetic lethality in cancer cells as a weapon to target hard-to-treat tumors.
Impact is building a global leading synthetic lethality product pipeline with the mission: Make an IMPACT on Cancer Treatment. This event is a good occasion to present Impact R&D progress, to hear advice and to discuss potential collaborations.
Wish a great success of the inaugural IMPACT 2020 R&D Day!
About Impact
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, and dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled a most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform, and is expanding to other novel synthetic lethality targets to broaden its pipeline. Impact has been invested by recognized venture capital firms including Lilly Asia Ventures.